
Sign up to save your podcasts
Or


In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices.
00:00 Introduction to Lung Cancer Research Podcast
00:37 Panel Introduction and Discussion Overview
01:18 Lung Cancer Screening in Australia
02:30 Impact of Screening on Diagnostic Services
06:45 Screening Program Benefits and Challenges
10:34 Future of Lung Cancer Screening
15:54 Advancements in Diagnostic Technology
20:57 Therapeutic Developments in Lung Cancer
24:34 New Drug Listings and Their Impact
40:04 Immunotherapy and Future Directions
44:13 Conclusion and Final Thoughts
Support TOGA
Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.
---------------
Connect with TOGA
Attend an Event: https://thoraciconcology.org.au/events/
Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/
Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/
Follow Us
LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
X (Twitter): https://x.com/TOGAANZ
Instagram: https://www.instagram.com/togaanz/
YouTube: https://www.youtube.com/@Thoracic_Oncology
---------------
Acknowledgement of Country
The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.
By Thoracic Oncology Group Of Australasia (TOGA)In this episode of 'Conversations in Lung Cancer Research,' hosted by Associate Professor Mal Itchens, a multidisciplinary panel delves into the ongoing advancements in lung cancer research in Australia and New Zealand. The panel includes Professor Nick Pavlakis from Royal North Shore Hospital and Associate Professor Lauren Troy from Royal Prince Alfred Sydney. Key topics discussed include the 2025 lung cancer screening program, anticipated pharmaceutical benefits scheme (PBS) drug listings for 2026, and the introduction of advanced diagnostic technologies. The conversation highlights the initial impacts of the lung cancer screening program, potential benefits of new ALK inhibitors, and the expanding role of immunotherapy. The episode also explores the future of diagnostic precision with the rise of interventional pulmonology and liquid biopsies. Additionally, it emphasises the growing importance of specialised lung cancer nursing and the integration of novel technologies in oncology practices.
00:00 Introduction to Lung Cancer Research Podcast
00:37 Panel Introduction and Discussion Overview
01:18 Lung Cancer Screening in Australia
02:30 Impact of Screening on Diagnostic Services
06:45 Screening Program Benefits and Challenges
10:34 Future of Lung Cancer Screening
15:54 Advancements in Diagnostic Technology
20:57 Therapeutic Developments in Lung Cancer
24:34 New Drug Listings and Their Impact
40:04 Immunotherapy and Future Directions
44:13 Conclusion and Final Thoughts
Support TOGA
Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.
---------------
Connect with TOGA
Attend an Event: https://thoraciconcology.org.au/events/
Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/
Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/
Follow Us
LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/
X (Twitter): https://x.com/TOGAANZ
Instagram: https://www.instagram.com/togaanz/
YouTube: https://www.youtube.com/@Thoracic_Oncology
---------------
Acknowledgement of Country
The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

27 Listeners

3 Listeners